



GO LIFE INTERNATIONAL LIMITED

(Incorporated in the Republic of Mauritius)

(Registration number: 098177 C1/GBL)

Primary Listing SEM share code: GOLI.N0000

Secondary Listing JSE share code: GLI ISIN: MU0330N00004

("the Company" or "the Group" or "Go Life")

**ABRIDGED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE, SIX AND NINE MONTHS ENDED 30 NOVEMBER 2019**

DIRECTORS' COMMENTARY

BACKGROUND

The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Category 1 Global Business License (License No - C110009034) issued by the Mauritius Financial Services Commission.

Go Life is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius ("SEM") on 7 July 2011. The Company successfully completed a secondary listing on the Alternative Exchange ("Alt-X") of the Johannesburg Stock Exchange ("JSE") on 23 November 2016.

PRIMARY OBJECTIVE

The initial focus of the Company was to compete in the supplementary nutraceutical and cosmeceutical markets by offering natural compounds that have been subjected to study and clinical trials. The focus has shifted somewhat and Go Life International is now a multi-faceted healthcare company, offering a comprehensive a diverse range of products and services.

Go Life International has continued to evolve through the careful acquisition of complementary Healthcare target companies, by focusing on those entities that will form part of the future of Healthcare.

COMPANY OUTLOOK

Go Life added to its family of companies Cryosave, in a Joint Venture with Esperite NV, the leading Stem Cell storage bank in South Africa in this period.

Whilst the Balance Sheet of Go Life International is strengthened by the BonHealthcare property portfolio, Go Life is undertaking a comprehensive review of the balance sheet in order release some equity held in those assets for liquidity and the funding of expansion plans within the new acquired entities.

SUBSEQUENT EVENTS

It is important to note that as announced by management at the time, Go Life Healthcare, a subsidiary of Go Life was placed into liquidation. The full implication of this is unfolding. We expect that there will be impairment of the underlying balance sheet.

Further to the above, notwithstanding the proposed restructuring of the BonHealthcare portfolio as indicated above, further information came to light in subsequent quarters on legal events that have placed this investment at risk of severe impairment. The rights of Go Life International as the shareholder of Go Life were impacted by legal claims within the Calitz Family Trust from who the properties were acquired. These proceedings had a direct and material impact on the BonHealthcare holdings.

DIVIDENDS

No dividends were authorized or paid during the period under review.

STATEMENT OF FINANCIAL POSITION

	THE GROUP Unaudited 3 MONTHS	THE GROUP Unaudited 6 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Audited 12 MONTHS
	31 MAY 2019	31 AUGUST 2019	30 NOVEMBER 2019	30 NOVEMBER 2018	28 FEBRUARY 2019
	USD	USD	USD	USD	USD
ASSETS					
Non - Current Assets	37 976 744	38 000 788	38 180 862	37 661 769	37 867 033
Investments in Associates	1 489 187	1 489 187	1 410 864	849 095	1 489 187
Intangible Assets	29 596 947	29 978 973	29 998 426	29 026 143	29 596 947
Property Plant and Machinery	6 890 610	6 532 628	6 771 572	7 786 531	6 439 347
Current Assets	294 297	278 441	293 898	1 313 558	297 194
Inventories	113 768	108 694	102 838	184 721	107 281
Trade and other Receivables	179 942	168 371	189 385	245 381	189 565
Cash and Cash Equivalents	587	1 376	1 675	883 456	348
Income taxes	-	-	-	-	-
TOTAL ASSETS	38 271 041	38 279 229	38 474 760	38 975 327	38 164 227
EQUITY					
Capital and Reserves	29 458 607	29 482 651	29 662 725	34 953 410	29 348 896
Share Capital	34 965 300	34 965 300	34 965 300	34 965 300	34 965 300
Accumulated Profit	(5 506 693)	(5 482 649)	(5 302 575)	(11 890)	(5 616 404)
Non Distributable Reserves	-	-	-	-	-
Foreign Currency Translation Reserve	-	-	-	-	-
LIABILITIES					
Non - Current Liabilities	7 971 807	8 037 440	8 278 563	3 612 296	7 971 808
Loan - Shareholders	6 426 652	6 445 931	6 639 309	3 487 325	6 426 653
Loan – third party	1 545 155	1 591 509	1 639 254	124 971	1 545 155
Current Liabilities	840 627	759 138	533 472	409 623	843 523
Trade and other Payables	718 782	629 292	407 486	409 623	602 111
Borrowings	121 845	129 846	125 986	-	105 674
Income Tax	-	-	-	-	-
TOTAL EQUITY AND LIABILITIES	38 271 041	38 279 229	38 474 760	38 975 327	38 164 227

STATEMENT OF PROFIT AND OTHER COMPREHENSIVE INCOME

	THE GROUP Unaudited 3 MONTHS	THE GROUP Unaudited 6 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Audited 12 MONTHS
	31 MAY 2019	31 AUGUST 2019	30 NOVEMBER 2019	30 NOVEMBER 2018	28 FEBRUARY 2019
	USD	USD	USD	USD	USD
Revenue	998 588	1 917 396	2 678 047	2 380 389	4 136 053
Expenses	(857 291)	(1 699 740)	(2 227 363)	(1 485 673)	(2 821 993)
PROFIT FROM OPERATIONS	141 296	217 656	450 684	894 716	1 328 308
Share of profits - Associates	39 032	58 085	84 829	114 839	14 248
Finance Income	-	-	-	-	-
Finance costs	(70 618)	(141 986)	(221 684)	(312 403)	(548 385)
PROFIT BEFORE TAXATION	109 711	133 755	313 829	697 152	654 339
Taxation	-	-	-	-	-
NET PROFIT AFTER TAXATION	109 711	133 755	313 829	697 152	654 339
Other Comprehensive income	-	-	-	-	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	109 711	133 755	313 829	697 152	654 339

RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS

	THE GROUP Unaudited 3 MONTHS	THE GROUP Unaudited 6 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Audited 12 MONTHS
	31 MAY 2019	31 AUGUST 2019	30 NOVEMBER 2019	30 NOVEMBER 2018	28 FEBRUARY 2019
		USD	USD	USD	USD
Basic earnings	109 711	133 755	313 829	697 152	654 339
Headline earnings	109 711	133 755	313 829	697 152	654 339
Weighted average number of shares	900 000 000	900 000 000	900 000 000	900 000 000	900 000 000
Basic and diluted earnings per share (USD cents)	0.0122	0.0148	0.0348	0.0775	0.0727
Headline earnings per share (USD cents)	0.0122	0.0148	0.0348	0.0775	0.0727

STATEMENT OF CASH FLOWS

	THE GROUP Unaudited 3 MONTHS	THE GROUP Unaudited 6 MONTHS	THE GROUP Unaudited 9 MONTHS	Unaudited 9 MONTHS	THE GROUP Audited 12 MONTHS
	31 MAY 2019	31 AUGUST 2019	30 NOVEMBER 2019	30 NOVEMBER 2018	28 FEBRUARY 2019
	USD	USD	USD	USD	USD
Net Cash (used in)/ from other operating activities				(68 054)	(444 313)
Cash from/(used in) investing activities					
Property, plant and equipment				226 817	128 063
Movement in net cash resources				158 763	572 367
Balance at the start of the year	348			572 724	573 724
Balance at the end of the period				731 487	348

STATEMENT OF CHANGES IN EQUITY

	Share USD	Revenue USD	Total USD
Balance as at 1 March 2019	34 965 300	(5 616 404)	29 348 896
Balance as at 30 November 2019	29 348 896		
Total Comprehensive Income for the period	-	313 829	29 662 725
Balance as at 30 NOVEMBER 2019	29 348 896	313 829	29 662 725

SEGMENTAL REPORTING – 9 MONTHS ENDED 30 NOVEMBER 2019

	Healthcare USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	2 099 687	493 531	84 829	2 678 047
Interest expenses	(297 050)	(314 258)	-	(411 308)
Income Tax	-	-	-	-
Net profit/(loss) for the period	49 727	179 273	84 829	313 829
Statement of financial position				
Total Assets	30 606 666	7 519 566	849 095	38 975 327
Total Borrowings	(4 853 779)	(3 424 784)	-	(8 278 563)

SEGMENTAL REPORTING – 9 MONTHS ENDED 30 NOVEMBER 2018

	Healthcare USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	1 857 712	522 677	114 839	2 495 228
Interest expenses	-	(312 403)	-	(312 403)
Income Tax	-	-	-	-
Net profit/(loss) for the period	372 039	210 274	114 839	697 152
Statement of financial position				
Total Assets	29 945 837	7 519 566	849 095	38 314 498
Total Borrowings	(720 434)	(3 487 325)	-	(4 207 759)

SEGMENTAL REPORTING – 12 MONTHS ENDED 28 FEB 2019

	Nutraceutical USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	3 364 292	757 510	14 248	4 136 053
Interest expenses	(396 067)	(152 345)	-	548 412
Income Tax				
Net profit/(loss) for the period	34 926	605 165	14 248	654 339
Statement of financial position				
Total Assets	29 894 141	6 439 347	1 830 739	38 164 227
Total Borrowings	(4 547 024)	(3 424 784)	-	(7 971 808)

Notes

The Company is required to publish financial results for the 3, 6 and 9 months ended 30 November 2019 in terms of the Listing Rule 12.19 of the SEM. The abridged unaudited consolidated financial statements for the 3 months ended 30 November 2018 ("Financial Statements") have been prepared in accordance with the measurement and recognition requirements of International Financial Reporting Standards ("IFRS"), the requirements of IAS 34: Interim Financial Reporting and the SEM Listing Rules and the JSE Listing Requirements.

The accounting policies adopted in the preparation of the Financial Statements are in terms of IFRS and are consistent with those applied in the preparation of the audited financial statements of the year ended 28 February 2018.

Copies of the abridged unaudited consolidated financial statements for the 9 months ended 30 November 2019 and the statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request to the at the registered office of the Company at 5th Floor, Atchia Building, Cnr Suffren & Eugene Laurent Streets, Port Louis 21001, Mauritius.

This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.20 and section 88 of the Securities Act of Mauritius 2005. The Board accepts full responsibility for the accuracy of the information contained in these Financial Statements. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 30 November 2019 that require any additional disclosure or adjustment to the Financial Statements.

Go Life has its primary listing on the Stock Exchange Mauritius and a secondary listing on the Alt-X of the JSE

By order of the Board

18 December 2020

For further information please contact:

FinAegis Ltd
(230) 213-2503

<p>Executive Directors: Mxolisi Motau Patrick Wysoczanski</p>	<p>Non-Executive Directors: Mohamed Yusuf Sooklall Peter Koll</p>
<p>JSE Sponsor: Arbor Capital Sponsors (PTY) Ltd</p>	